1 min read
CMA opens four new pharma antitrust probes
On 13 and 18 October 2017 the CMA announced that it had launched four separate antitrust investigations into alleged anti-competitive practices regarding generic products in the pharmaceutical industry. The four investigations cover alleged anti-competitive agreements, concerted practices and, in some cases, abuse of dominance. These new investigations demonstrate that the CMA continues to be unafraid to take a robust approach to investigating anti-competitive conduct relating to generic drugs.
Also in this newsletter
- European Commission raids German car manufacturers
- General Court rules that watchmakers may restrict supply of parts to authorised repairers only
- Hong Kong Competition Tribunal issues judgment on the right against self-incrimination
Competition & Regulatory Newsletter (18 - 31 Oct 2017)